Brought to you by 
Igeneon and Novartis develop cancer therapy
16 Jul 2003
Executive Summary
Under an option agreement the companies signed in 2000, Austrian cancer immunotherapy company igeneon licensed exclusive worldwide development and marketing rights to Novartis' IGN301, a cancer vaccine candidate in Phase I for epithelial cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Igeneon and Novartis develop cancer therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice